NCT05155293View on ClinicalTrials.gov

Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)

PHASE3CompletedINTERVENTIONAL
Enrollment

413

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

November 17, 2023

Study Completion Date

September 23, 2024

Conditions
Neovascular (Wet) AMD
Interventions
DRUG

AVT06 (proposed aflibercept biosimilar)

Patients will receive IVT injections of AVT06

DRUG

Eylea® (Aflibercept)

Patients will receive IVT injections of Eylea®

Trial Locations (6)

1002

Pauls Stradins Clinical University Hospital SLLC, Riga

10006

"Riga East University Hospital Clinical Centre Bikernieki", Riga

35601

Nemocnicni lekarna Sokolov, Sokolov

Unknown

JSC Evex Medical Corporation, Tbilisi

812 0011

Keneikai Hayashi Eye Hospital, Fukuoka

911 71

Fakultna Nemocnica Trencin, Trenčín

All Listed Sponsors
lead

Alvotech Swiss AG

INDUSTRY